NovaBay Pharmaceuticals (NBY) Soars 19% Following Stablecoin Transformation Announcement

Key Highlights

• Shares of NovaBay Pharmaceuticals climbed approximately 19% following the announcement of its transformation into Stablecoin Development Corporation
• The firm will transition its stock symbol from NBY to SDEV starting April 3
• The company has accumulated 2.06 billion SKY tokens — representing approximately 8.8% of circulating supply — valued at roughly $150 million
• The strategic shift was financed through a $134 million private funding round featuring Tether Investments and Framework Ventures
• While Monday brought gains, the stock has declined over 95% since the beginning of the year

Shares of NovaBay Pharmaceuticals experienced a dramatic rally of nearly 19% on Monday as the company unveiled plans to completely abandon its eye care pharmaceutical business in favor of the digital stablecoin sector.

NovaBay Pharmaceuticals, Inc., NBY

The biotech firm announced its intention to adopt the name Stablecoin Development Corporation. Along with the rebrand, the company’s trading symbol will transition from NBY to SDEV on April 3.

This strategic direction isn’t completely unexpected. In January, NovaBay submitted regulatory filings with the SEC describing its plans to function as an “on-chain holding company framework focused on long-duration participation in protocol-level digital asset ecosystems.”

NBY shares jumped 19% to approximately $1.38–$1.40 following the announcement. However, despite this rally, the stock remains deeply underwater, having lost more than 95% of its value year to date.

Massive SKY Token Position Forms Core of New Business Model

The foundation of NovaBay’s reimagined business strategy revolves around its substantial holdings in SKY, the governance token powering the Sky protocol — which is the rebranded MakerDAO platform that supports the USDS stablecoin.

According to March 16 disclosures, the company controls approximately 2.06 billion SKY tokens. This stake accounts for roughly 8.8% of the token’s total available supply and carries an estimated market value of $150 million. SKY currently trades at $0.073 per CoinGecko data, showing a 15% gain year to date despite broader cryptocurrency market weakness.

The substantial token position was established using capital from a $134 million private placement that closed in January. Major participants in that funding round included Framework Ventures, Tether Investments, and the Sky Frontier Foundation.

Staking Returns and Expansion Strategy

The company’s SKY staking operations have already produced 26.6 million SKY tokens in aggregate rewards. Management indicated plans to continue acquiring additional SKY tokens through open market purchases.

Currently, SKY stands as the sole digital asset authorized under NovaBay’s operational and risk governance framework. However, the company has identified yield-generating stablecoins as a strategic priority for future expansion.

Established in 2000 in California, NovaBay dedicated more than twenty years to developing eye care biotechnology products before executing this dramatic strategic transformation.

The pivot arrives as stablecoin regulatory frameworks gain momentum in the nation’s capital. Congress recently achieved an “agreement in principle” regarding the treatment of stablecoin yield within broader cryptocurrency market structure legislation — representing progress toward comprehensive Senate Banking Committee regulatory measures.

The company’s revised strategy emphasizes acquiring and holding protocol-native digital assets over extended timeframes to capture value from what management terms “protocol-level economic activity.”

Total staking rewards have reached 26.6 million SKY tokens to date, with ongoing initiatives aimed at expanding this position substantially.

The post NovaBay Pharmaceuticals (NBY) Soars 19% Following Stablecoin Transformation Announcement appeared first on Blockonomi.